Oxadiazole derivatives active on sphingosine-1-phosphate (s1p)

Abstract

The present invention relates to a novel oxadiazole derivative having pharmacological activity, processes for its preparation, pharmaceutical compositions containing it and its use in the treatment of various disorders.

1 . 3-[6-(5-{3-Cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-5-methyl-3,4-dihydro-2(1H)-isoquinolinyl]propanoic acid and pharmaceutically acceptable salts thereof. 
   
   
       2 . A method of treating multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non-insulin dependent diabetes, which comprises administering to a patient in need thereof, a compound of  claim 1 . 
   
   
       3 . A method according to  claim 2 , wherein the condition is psoriasis. 
   
   
       4 . A pharmaceutical composition comprising a compound according to  claim 1  and a pharmaceutically acceptable carrier or excipient.